BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 29804232)

  • 1. Early Downregulation of p75
    Suelves N; Miguez A; López-Benito S; Barriga GG; Giralt A; Alvarez-Periel E; Arévalo JC; Alberch J; Ginés S; Brito V
    Mol Neurobiol; 2019 Feb; 56(2):935-953. PubMed ID: 29804232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
    Brito V; Puigdellívol M; Giralt A; del Toro D; Alberch J; Ginés S
    Cell Death Dis; 2013 Apr; 4(4):e595. PubMed ID: 23598407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.
    Miguez A; García-Díaz Barriga G; Brito V; Straccia M; Giralt A; Ginés S; Canals JM; Alberch J
    Hum Mol Genet; 2015 Sep; 24(17):4958-70. PubMed ID: 26063761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7,8-dihydroxyflavone ameliorates cognitive and motor deficits in a Huntington's disease mouse model through specific activation of the PLCγ1 pathway.
    García-Díaz Barriga G; Giralt A; Anglada-Huguet M; Gaja-Capdevila N; Orlandi JG; Soriano J; Canals JM; Alberch J
    Hum Mol Genet; 2017 Aug; 26(16):3144-3160. PubMed ID: 28541476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.
    Simmons DA; Belichenko NP; Yang T; Condon C; Monbureau M; Shamloo M; Jing D; Massa SM; Longo FM
    J Neurosci; 2013 Nov; 33(48):18712-27. PubMed ID: 24285878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p75 neurotrophin receptor augments survival signaling in the striatum of pre-symptomatic Q175(WT/HD) mice.
    Wehner AB; Milen AM; Albin RL; Pierchala BA
    Neuroscience; 2016 Jun; 324():297-306. PubMed ID: 26947127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites.
    Liot G; Zala D; Pla P; Mottet G; Piel M; Saudou F
    J Neurosci; 2013 Apr; 33(15):6298-309. PubMed ID: 23575829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction.
    Brito V; Giralt A; Enriquez-Barreto L; Puigdellívol M; Suelves N; Zamora-Moratalla A; Ballesteros JJ; Martín ED; Dominguez-Iturza N; Morales M; Alberch J; Ginés S
    J Clin Invest; 2014 Oct; 124(10):4411-28. PubMed ID: 25180603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.
    Anglada-Huguet M; Giralt A; Rué L; Alberch J; Xifró X
    Biochim Biophys Acta; 2016 Jul; 1862(7):1255-66. PubMed ID: 27063456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of BDNF and Full-Length TrkB Receptor Ameliorate Striatal Neural Survival in Huntington's Disease.
    Silva A; Naia L; Dominguez A; Ribeiro M; Rodrigues J; Vieira OV; Lessmann V; Rego AC
    Neurodegener Dis; 2015; 15(4):207-18. PubMed ID: 25896770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease.
    Plotkin JL; Day M; Peterson JD; Xie Z; Kress GJ; Rafalovich I; Kondapalli J; Gertler TS; Flajolet M; Greengard P; Stavarache M; Kaplitt MG; Rosinski J; Chan CS; Surmeier DJ
    Neuron; 2014 Jul; 83(1):178-88. PubMed ID: 24991961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease.
    Zhao X; Chen XQ; Han E; Hu Y; Paik P; Ding Z; Overman J; Lau AL; Shahmoradian SH; Chiu W; Thompson LM; Wu C; Mobley WC
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5655-64. PubMed ID: 27601642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.
    Canals JM; Pineda JR; Torres-Peraza JF; Bosch M; Martín-Ibañez R; Muñoz MT; Mengod G; Ernfors P; Alberch J
    J Neurosci; 2004 Sep; 24(35):7727-39. PubMed ID: 15342740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease.
    Zuccato C; Marullo M; Conforti P; MacDonald ME; Tartari M; Cattaneo E
    Brain Pathol; 2008 Apr; 18(2):225-38. PubMed ID: 18093249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington's disease.
    Connor B; Sun Y; von Hieber D; Tang SK; Jones KS; Maucksch C
    Gene Ther; 2016 Mar; 23(3):283-95. PubMed ID: 26704721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression.
    Ginés S; Paoletti P; Alberch J
    J Biol Chem; 2010 Jul; 285(28):21537-48. PubMed ID: 20442398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
    Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
    Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease.
    Smith GA; Rocha EM; McLean JR; Hayes MA; Izen SC; Isacson O; Hallett PJ
    Hum Mol Genet; 2014 Sep; 23(17):4510-27. PubMed ID: 24728190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.